Thomas E Hutson, DO, PharmD FACP
Director, GU Oncology Program, Co-Director, Urologic Cancer Research and Treatment Center, Texas Oncology/ Baylor Sammons Cancer Center, Professor of Medicine, Texas AM College of Medicine presents LENVATINIB + EVEROLIMUS A powerful treatment for refractory RCC at the 2016 annual International Kidney Cancer Symposium.
LENVATINIB + EVEROLIMUS A powerful treatment for refractory RCC.
